TriSalus Life Sciences (TLSIW) Debt to Equity (2022 - 2025)
TriSalus Life Sciences' Debt to Equity history spans 4 years, with the latest figure at -$0.98 for Q4 2025.
- For Q4 2025, Debt to Equity fell 14.43% year-over-year to -$0.98; the TTM value through Dec 2025 reached -$0.98, down 14.43%, while the annual FY2025 figure was -$0.98, 14.43% down from the prior year.
- Debt to Equity reached -$0.98 in Q4 2025 per TLSIW's latest filing, up from -$1.23 in the prior quarter.
- In the past five years, Debt to Equity ranged from a high of -$0.03 in Q1 2023 to a low of -$1.66 in Q2 2025.
- Average Debt to Equity over 4 years is -$0.77, with a median of -$0.89 recorded in 2024.
- Peak YoY movement for Debt to Equity: plummeted 1564.01% in 2024, then dropped 14.43% in 2025.
- A 4-year view of Debt to Equity shows it stood at -$0.09 in 2022, then surged by 43.3% to -$0.05 in 2023, then tumbled by 1584.32% to -$0.85 in 2024, then dropped by 14.43% to -$0.98 in 2025.
- Per Business Quant, the three most recent readings for TLSIW's Debt to Equity are -$0.98 (Q4 2025), -$1.23 (Q3 2025), and -$1.66 (Q2 2025).